The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone

• Published in: Progress in neuro-psychopharmacology & biological psychiatry 2011-07, Vol.35 (5), p.1273-1278
• Main Authors: Lee, Nam Young, Kim, Se Hyun, Jung, Dong Chung, Kim, Eun Young, Yu, Han Young, Sung, Ki Hye, Kang, Ung Gu, Ahn, Yong Min, Kim, Yong Sik
• Format: Article
• Language: English
• Subjects: Adult; Adult and adolescent clinical studies; Age Factors; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Aripiprazole; Asian Continental Ancestry Group; Benzodiazepines - adverse effects; Benzodiazepines - therapeutic use; Biological and medical sciences; Cohort Studies; Databases, Factual; Female; Hospitals, University; Humans; Indirectly standardized prevalence ratio; Male; Medical Records; Medical sciences; Metabolic diseases; Metabolic syndrome; Metabolic Syndrome - chemically induced; Metabolic Syndrome - drug therapy; Metabolic Syndrome - epidemiology; Middle Aged; Miscellaneous; Neuropharmacology; Olanzapine; Other metabolic disorders; Pharmacology. Drug treatments; Piperazines - adverse effects; Piperazines - therapeutic use; Psycholeptics: tranquillizer, neuroleptic; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Psychoses; Quinolones - adverse effects; Quinolones - therapeutic use; Republic of Korea - epidemiology; Retrospective Studies; Risperidone; Risperidone - adverse effects; Risperidone - therapeutic use; Schizophrenia; Schizophrenia - drug therapy; Schizophrenia - epidemiology; Sex Factors; Young Adult
• ISSN: 0278-5846; 1878-4216
• DOI: 10.1016/j.pnpbp.2011.03.022

Second-generation antipsychotics (SGAs) increase the risk of metabolic syndrome (MetS). Although ethnicity also contributes to MetS risk, the majority of the studies on the relationship of SGAs to this syndrome come from Western countries, whereas few reports have come from Asian countries, especially regarding patients taking a single SGA. We reviewed the electronic medical records of patients with schizophrenia who received aripiprazole, olanzapine or risperidone monotherapies for at least three months. We evaluated the prevalence of MetS in our sample as well as the indirect standardized prevalence ratio (ISPR) using data from the 4th Korean National Health and Nutrition Examination Survey (KNHNES, 2007). The prevalence of MetS in our sample (n=145) was 31.7%, and the ISPR was 2.09. Male patients had a higher prevalence of MetS than female patients (odds ratio [OR]=4.18, 95% CI=1.93–9.03). The ISPR of male patients was 2.67 and statistically significant, whereas the ISPR of female patients was not significant. In our sample, the frequency of abnormal MetS subcomponents occurred in descending order: increased waist circumference, increased triglyceride levels, decreased HDL-cholesterol levels, elevated blood pressure and elevated fasting blood glucose levels. Patients who received aripiprazole were significantly less likely to have MetS. However, a logistic regression showed that age and sex, but not the type of antipsychotic, its dose or the use of antidepressants, were significantly related to the presence of MetS. There were no statistically significant differences among SGAs in terms of MetS subcomponent abnormalities of after adjusting for age and sex. In conclusion, only male Korean patients with schizophrenia who received a monotherapy of aripiprazole, olanzapine or risperidone for more than three months were more likely to have MetS than the general population. ► The prevalence of metabolic syndrome in patients with schizophrenia is reported variously. ► We examined this in Korean patients receiving an antipsychotic monotherapy. ► The indirectly standardized prevalence ratio of metabolic syndrome was examined. ► Male patients were more likely to have metabolic syndrome than general population.